Originally published June 25.

Through a partnership with Tesaro, Myriad Genetics this year will use BRACAnalysis to help the biotechnology firm better characterize whether the BRCA mutation status of ovarian and breast cancer patients impacts their ability to respond to the investigational PARP inhibitor niraparib.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.